# US 2023/0054546 A1 · Use of oligosaccharide riclinoctaose in preparation of drug for treating and/or preventing ischemia-reperfusion injury (iri)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054546 A1
- Document ID: US20230054546A1
- Status: Published application
- Kind: A1
- Application number: 17/816,871
- Filed: 2022-08-02
- Published: 2023-02-23
- Earliest claimed: 2021-08-03
- Assignees: Nanjing Southern Element Biotechnology Co., Ltd.
- Applicants: Nanjing Southern Element Biotechnology Co., Ltd.
- Inventors: Jianfa ZHANG; Ni WANG; Yang ZHAO
- Web page: https://patentgrep.com/patent/US20230054546A1

## CPC

- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Oligosaccharide riclinoctaose is used in preparation of a drug for treating and/or preventing ischemia-reperfusion injury (IRI). The oligosaccharide riclinoctaose has a structural formula as follows: The oligosaccharide riclinoctaose can significantly relieve postoperative liver injury, kidney injury, and brain injury in ischemia-reperfusion mice.

## Claims

### Claim 1

A method for treating ischemia-reperfusion injury (IRI) by oligosaccharide riclinoctaose, wherein the oligosaccharide riclinoctaose has a structural formula as follows:

### Claim 2 (depends on 1)

The method according to claim 1, wherein in the oligosaccharide riclinoctaose, seven glucose residues and one galactose residue are ligated as follows:
D-Glcp(4,6-pyr)-β-(1→3)-D-Glcp-β-(1→3)-D-Glcp-β-(1→6)-D-Glcp-β-(1→6)-D-Glcp-β-(1→4)-D-Glcp-β-(1→4)-D-Glcp-β-(1→3)-D-Galp.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the IRI is caused by blood circulation disorder due to traumatic shock, surgery, organ transplantation, burn, frostbite, or thrombus.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the IRI is hepatic IRI (HIRI), renal IRI (RIRI), cerebral IRI (CIRI), or myocardial IRI (MIRI).

### Claim 5 (depends on 1)

The method according to claim 1, wherein the drug is administered to a human being or a non-human animal.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the drug is administered at a dosage of 20 mg/mL to 40 mg/mL.

### Claim 7 (depends on 1)

The method according to claim 1, wherein a pharmaceutical carrier of the drug is an isotonic NaCl solution, an isotonic glucose solution, or an isotonic solution containing a buffer system.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the pharmaceutical carrier of the drug is a 0.9% normal saline.
